NCT00319566View on ClinicalTrials.gov

Heart and Estrogen-Progestin Replacement Study (HERS)

PHASE3CompletedINTERVENTIONAL
Enrollment

2,430

Participants

Timeline

Start Date

July 31, 1992

Study Completion Date

July 31, 2001

Conditions
Coronary Heart Disease
Interventions
DRUG

Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT00319566 - Heart and Estrogen-Progestin Replacement Study (HERS) | Biotech Hunter | Biotech Hunter